Biotech · Private company
Theradex
Track this companyFree. Adds Theradex to your Dealase workspace and tells you when its record changes.
Clinical trials84 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- HydroxyureaPhase 2 · Leukemia, Myelomonocytic, ChronicClinicalTrials.gov · fetched Nov 12, 2026
- PacritinibPhase 2 · Leukemia, Myelomonocytic, ChronicClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic LeukemiaPHASE2 · RECRUITING · started Jan 1, 2026ClinicalTrials.gov NCT07033598 · fetched Nov 12, 2026
- Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable TumorsPHASE2 · RECRUITING · started Dec 21, 2023ClinicalTrials.gov NCT05280314 · fetched Nov 12, 2026
- A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic SyndromesPHASE1_PHASE2 · RECRUITING · started Apr 25, 2023ClinicalTrials.gov NCT05732103 · fetched Nov 12, 2026
- IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBCPHASE2 · COMPLETED · started Apr 11, 2022ClinicalTrials.gov NCT05077709 · fetched Nov 12, 2026
- Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)PHASE1_PHASE2 · RECRUITING · started Nov 24, 2021ClinicalTrials.gov NCT04061421 · fetched Nov 12, 2026
- L-DOS47 Plus Doxorubicin in Advanced Pancreatic CancerPHASE1_PHASE2 · TERMINATED · started Dec 11, 2019ClinicalTrials.gov NCT04203641 · fetched Nov 12, 2026
- MEN1703 (SEL24) in Participants With Acute Myeloid LeukemiaPHASE1_PHASE2 · COMPLETED · started Mar 10, 2017ClinicalTrials.gov NCT03008187 · fetched Nov 12, 2026
- A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLCPHASE1 · TERMINATED · started Apr 20, 2015ClinicalTrials.gov NCT02309892 · fetched Nov 12, 2026